Will Selpercatinib be included in medical insurance in 2025?

Selpercatinib/Selpercatinib is a targeted therapy drug mainly used to treat specific types of non-small cell lung cancer (NSCLC) and other related tumors. The indications of this drug are mainly for patients with tumors with rearrangements of the RET gene. The RET gene is a proto-oncogene and plays an important role in the occurrence and development of certain tumors. Seputinib can effectively prevent the proliferation and survival of tumor cells by selectively inhibiting the activity of RET kinase, thus exerting anti-tumor effects.

In clinical trials, seputinib has shown good efficacy, especially in patients who have progressed after multiple treatments, showing a high objective response rate and sustained survival benefit. This makes it gradually become an important treatment option in the treatment of RET fusion-positive non-small cell lung cancer and other fields. In addition, seputinib has also been studied for the treatment of other types of tumors, such as thyroid cancer, further expanding its scope of indications.

Aboutthere is currently no precise information on whether it will be included in medical insurance in 2025. The medical insurance access of a drug usually depends on multiple factors, including the results of clinical trials, cost-benefit analysis of the drug, adjustments to national medical insurance policies, and market demand. If seputinib continues to show significant efficacy and safety in future clinical applications, and is economically reasonable and cost-effective, then it may be recognized in the future medical insurance directory.

However, the process for drugs to enter medical insurance is relatively complex and involves review by experts in the industry, economic evaluation and the formulation of relevant policies, so the specific time is difficult to predict. While waiting for changes in medical insurance policies, patients can pay attention to relevant clinical research and drug trends in order to obtain timely information and make appropriate treatment choices.

References:https://www.prnewswire.com/news-releases/the-china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers-301644366.html